Jazz Pharmaceuticals Management

Management criteria checks 3/4

Jazz Pharmaceuticals' CEO is Bruce Cozadd, appointed in Jan 2003, has a tenure of 21.33 years. total yearly compensation is $15.34M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth R$178.16M. The average tenure of the management team and the board of directors is 4.7 years and 11.4 years respectively.

Key information

Bruce Cozadd

Chief executive officer

US$15.3m

Total compensation

CEO salary percentage	7.8%
CEO tenure	21.3yrs
CEO ownership	0.5%
Management average tenure	4.7yrs
Board average tenure	11.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bruce Cozadd's remuneration changed compared to Jazz Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$331m
Dec 31 2023	US$15m	US$1m	US$415m
Sep 30 2023	n/a	n/a	US$80m
Jun 30 2023	n/a	n/a	-US$87m
Mar 31 2023	n/a	n/a	-US$156m
Dec 31 2022	US$17m	US$1m	-US$224m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$52m
Mar 31 2022	n/a	n/a	-US$450m
Dec 31 2021	US$16m	US$1m	-US$330m
Sep 30 2021	n/a	n/a	-US$161m
Jun 30 2021	n/a	n/a	US$40m
Mar 31 2021	n/a	n/a	US$518m
Dec 31 2020	US$13m	US$1m	US$239m
Sep 30 2020	n/a	n/a	US$179m
Jun 30 2020	n/a	n/a	US$133m
Mar 31 2020	n/a	n/a	US$280m
Dec 31 2019	US$15m	US$1m	US$523m
Sep 30 2019	n/a	n/a	US$609m
Jun 30 2019	n/a	n/a	US$656m
Mar 31 2019	n/a	n/a	US$486m
Dec 31 2018	US$11m	US$979k	US$447m
Sep 30 2018	n/a	n/a	US$520m
Jun 30 2018	n/a	n/a	US$434m
Mar 31 2018	n/a	n/a	US$447m
Dec 31 2017	US$10m	US$950k	US$488m

Compensation vs Market: Bruce's total compensation ($USD15.34M) is above average for companies of similar size in the BR market ($USD2.60M).

Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.

CEO

Bruce Cozadd (59 yo)

21.3yrs

Tenure

US$15,341,235

Compensation

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bruce Cozadd	Co-Founder	21.3yrs	US$15.34m	0.51% $ 178.2m
Renee Gala	President & COO	less than a year	US$5.43m	0.027% $ 9.4m
Patricia Carr	Senior VP & Chief Accounting Officer	4.8yrs	US$1.40m	0% $ 0
Neena Patil	Executive VP & Chief Legal Officer	4.8yrs	US$3.88m	0.026% $ 9.0m
Robert Iannone	Executive VP and Global Head of Research & Development	5yrs	US$4.98m	0.045% $ 15.9m
Philip Johnson	Executive VP & CFO	less than a year	no data	0.019% $ 6.8m
Andrea Flynn	VP & Head of Investor Relations	no data	no data	no data
Heidi Manna	Executive VP & Chief People Officer	5.5yrs	no data	no data
Jed Black	Senior Vice President of Sleep & CNS Medicine	no data	no data	no data
Samantha Pearce	Senior Vice President of Europe & International	4.2yrs	no data	0.023% $ 8.0m
John Miller	Senior Vice President of Corporate Strategy	4.7yrs	no data	no data
Mary Henderson	Senior Vice President of Technical Operations	less than a year	no data	no data

4.7yrs

Average Tenure

52yo

Average Age

Experienced Management: J2AZ34's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Bruce Cozadd	Co-Founder	21.3yrs	US$15.34m	0.51% $ 178.2m
Kenneth O'Keefe	Independent Director	20.3yrs	US$513.77k	0.042% $ 14.7m
Seamus Mulligan	Independent Director	12.3yrs	US$531.27k	1.88% $ 659.3m
Peter Gray	Independent Director	11yrs	US$533.77k	0.021% $ 7.3m
Norbert Riedel	Independent Director	11yrs	US$533.77k	0.017% $ 6.0m
Patrick Gerald Enright	Independent Director	14.8yrs	US$526.27k	0.029% $ 10.1m
Rick Winningham	Lead Independent Director	14yrs	US$571.27k	0.012% $ 4.2m
Jennifer Cook	Independent Non-Executive Director	3.4yrs	US$533.77k	0.0061% $ 2.2m
Catherine Sohn	Independent Director	11.8yrs	US$523.77k	0.019% $ 6.7m
Heather McSharry	Independent Director	11yrs	US$543.77k	0.022% $ 7.7m
Mark Smith	Independent Non-Executive Director	3.4yrs	US$521.27k	0.0061% $ 2.2m
Anne O'Riordan	Independent Director	5.3yrs	US$523.77k	0.015% $ 5.3m

11.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: J2AZ34's board of directors are seasoned and experienced ( 11.4 years average tenure).

Jazz Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc Announces Management Changes

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 28, 2022

Recent updates

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Management Changes

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023

Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn)

Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022

Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

Jazz Pharmaceuticals plc Updates Earnings Guidance for the Year 2022

Jazz Pharmaceuticals plc to Report Q2, 2022 Results on Aug 03, 2022

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 28, 2022

Jazz Pharmaceuticals plc Presents Positive Data from Phase 2/3 Trial of Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma At the ASCO 2022 Annual Meeting

Jazz Pharmaceuticals plc Raises Financial Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Q1, 2022 Results on May 04, 2022

Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, Including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types

Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million.

Jazz Pharmaceuticals plc Provides Revenue Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Fiscal Year 2021 Results on Mar 01, 2022

Jazz Pharmaceuticals plc Completes U.S. FDA Supplemental Biologics License Application for Rylaze

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age